ATE218132T1 - Azol-derivate - Google Patents
Azol-derivateInfo
- Publication number
- ATE218132T1 ATE218132T1 AT95934280T AT95934280T ATE218132T1 AT E218132 T1 ATE218132 T1 AT E218132T1 AT 95934280 T AT95934280 T AT 95934280T AT 95934280 T AT95934280 T AT 95934280T AT E218132 T1 ATE218132 T1 AT E218132T1
- Authority
- AT
- Austria
- Prior art keywords
- same
- represent
- hydrogen
- different
- amino
- Prior art date
Links
- 150000007980 azole derivatives Chemical class 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 230000003042 antagnostic effect Effects 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- 208000014644 Brain disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- -1 cyano, tetrazolyl Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 150000002617 leukotrienes Chemical class 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/26—Radicals substituted by sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Photoreceptors In Electrophotography (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP24948894 | 1994-10-14 | ||
| JP25112194 | 1994-10-18 | ||
| PCT/JP1995/002085 WO1996011916A1 (en) | 1994-10-14 | 1995-10-12 | Azole derivative |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE218132T1 true ATE218132T1 (de) | 2002-06-15 |
Family
ID=26539322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT95934280T ATE218132T1 (de) | 1994-10-14 | 1995-10-12 | Azol-derivate |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5981559A (de) |
| EP (1) | EP0786457B1 (de) |
| JP (1) | JP3061862B2 (de) |
| KR (1) | KR100386392B1 (de) |
| CN (1) | CN1107059C (de) |
| AT (1) | ATE218132T1 (de) |
| AU (1) | AU699476B2 (de) |
| CA (1) | CA2202623A1 (de) |
| DE (1) | DE69526862T2 (de) |
| FI (1) | FI971510A0 (de) |
| HU (1) | HUT77609A (de) |
| MX (1) | MX9702670A (de) |
| NO (1) | NO309268B1 (de) |
| RU (1) | RU2161612C2 (de) |
| TW (1) | TW381088B (de) |
| WO (1) | WO1996011916A1 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998057935A1 (en) * | 1997-06-17 | 1998-12-23 | Kaken Pharmaceutical Co., Ltd. | 2-sulfamoylbenzoic acid derivatives |
| JP2004137284A (ja) * | 1997-06-17 | 2004-05-13 | Kaken Pharmaceut Co Ltd | ２−スルファモイル安息香酸誘導体 |
| US6376671B1 (en) | 1997-06-17 | 2002-04-23 | Kaken Pharmaceutical Co., Ltd. | 2-sulfamoylbenzoic acid derivatives |
| EP1652839A3 (de) * | 1999-10-28 | 2006-07-05 | Daiichi Pharmaceutical Co., Ltd. | Pumpeninhibitoren zur Freisetzung von Medikamenten |
| US7176243B2 (en) * | 2000-06-02 | 2007-02-13 | The General Hospital Corporation | CaR receptor as a mediator of migratory cell chemotaxis and/or chemokinesis |
| WO2002087589A1 (en) * | 2001-04-26 | 2002-11-07 | Daiichi Pharmaceutical Co., Ltd. | Medicine for inhibiting drug elimination pump |
| US7056917B2 (en) * | 2001-04-26 | 2006-06-06 | Daiichi Pharmaceutical Co., Ltd. | Drug efflux pump inhibitor |
| CA2502357A1 (en) * | 2002-10-17 | 2004-04-29 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction; methods of treatment |
| US7507531B2 (en) * | 2002-10-17 | 2009-03-24 | Decode Genetics Chf. | Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction |
| US7851486B2 (en) * | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
| US20060019269A1 (en) * | 2002-10-17 | 2006-01-26 | Decode Genetics, Inc. | Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment |
| US20080293750A1 (en) * | 2002-10-17 | 2008-11-27 | Anna Helgadottir | Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment |
| US20050272051A1 (en) * | 2003-09-17 | 2005-12-08 | Decode Genetics Ehf. | Methods of preventing or treating recurrence of myocardial infarction |
| US8158362B2 (en) * | 2005-03-30 | 2012-04-17 | Decode Genetics Ehf. | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype |
| US20100216863A1 (en) * | 2004-01-30 | 2010-08-26 | Decode Genetics Ehf. | Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment |
| CN101237853A (zh) * | 2005-05-18 | 2008-08-06 | 普马特里克斯公司 | 改变粘膜内衬生物物理特性的配方 |
| JP5175866B2 (ja) | 2007-02-22 | 2013-04-03 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Ｇタンパク質共役受容体を調節するための化合物および方法 |
| EP2611438B1 (de) | 2010-08-30 | 2020-04-01 | Pulmatrix Operating Company, Inc. | Trockenpulverformulierungen und verfahren zur behandlung von lungenerkrankugen |
| WO2012030647A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder |
| DK2621488T3 (en) | 2010-09-29 | 2019-03-04 | Pulmatrix Operating Co Inc | CATIONIC DRY POWDER |
| JP5877204B2 (ja) | 2010-09-29 | 2016-03-02 | パルマトリックス，インコーポレイテッド | 吸入用の一価金属カチオン乾燥粉末 |
| CN107596518B (zh) | 2012-02-29 | 2021-04-23 | 普马特里克斯营业公司 | 可吸入干粉剂 |
| WO2014165303A1 (en) | 2013-04-01 | 2014-10-09 | Pulmatrix, Inc. | Tiotropium dry powders |
| JP7174757B2 (ja) | 2017-07-04 | 2022-11-17 | イントゥーセル，インコーポレーティッド | 切断可能なリンカーを含む化合物及びその使用 |
| EA202191855A1 (ru) | 2019-01-03 | 2021-11-19 | Интоселл, Инк. | Соединения, содержащие расщепляемый линкер, и способы их применения |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS532613A (en) * | 1976-06-24 | 1978-01-11 | Shinkou Burain Kk | Crepe forming method for paper |
| JPS63258854A (ja) * | 1987-04-16 | 1988-10-26 | Mitsubishi Kasei Corp | カルボキシスチレン誘導体およびそれを有効成分とする薬剤 |
| ZA894913B (en) * | 1988-07-12 | 1990-03-28 | Ici Pharma | Heterocyclic compounds |
| JPH0832688B2 (ja) * | 1990-10-16 | 1996-03-29 | テルモ株式会社 | フェノキシ酢酸誘導体及びこれを含有する医薬製剤 |
| JPH0532613A (ja) * | 1991-07-29 | 1993-02-09 | Terumo Corp | フエノキシ酢酸誘導体およびこれを含有する医薬製剤 |
| US5273986A (en) * | 1992-07-02 | 1993-12-28 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
-
1995
- 1995-10-12 AT AT95934280T patent/ATE218132T1/de not_active IP Right Cessation
- 1995-10-12 RU RU97107457/04A patent/RU2161612C2/ru active
- 1995-10-12 CA CA002202623A patent/CA2202623A1/en not_active Abandoned
- 1995-10-12 WO PCT/JP1995/002085 patent/WO1996011916A1/ja not_active Ceased
- 1995-10-12 DE DE69526862T patent/DE69526862T2/de not_active Expired - Fee Related
- 1995-10-12 CN CN95195649A patent/CN1107059C/zh not_active Expired - Fee Related
- 1995-10-12 EP EP95934280A patent/EP0786457B1/de not_active Expired - Lifetime
- 1995-10-12 HU HU9702271A patent/HUT77609A/hu unknown
- 1995-10-12 US US08/809,466 patent/US5981559A/en not_active Expired - Fee Related
- 1995-10-12 JP JP8513092A patent/JP3061862B2/ja not_active Expired - Lifetime
- 1995-10-12 MX MX9702670A patent/MX9702670A/es not_active IP Right Cessation
- 1995-10-12 AU AU36730/95A patent/AU699476B2/en not_active Ceased
- 1995-10-12 TW TW084110701A patent/TW381088B/zh not_active IP Right Cessation
- 1995-10-12 KR KR1019970701880A patent/KR100386392B1/ko not_active Expired - Fee Related
-
1997
- 1997-04-11 FI FI971510A patent/FI971510A0/fi unknown
- 1997-04-11 NO NO971685A patent/NO309268B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR970706265A (ko) | 1997-11-03 |
| KR100386392B1 (ko) | 2003-10-11 |
| TW381088B (en) | 2000-02-01 |
| EP0786457A1 (de) | 1997-07-30 |
| CN1160397A (zh) | 1997-09-24 |
| NO309268B1 (no) | 2001-01-08 |
| MX9702670A (es) | 1997-07-31 |
| RU2161612C2 (ru) | 2001-01-10 |
| DE69526862D1 (de) | 2002-07-04 |
| CN1107059C (zh) | 2003-04-30 |
| EP0786457A4 (de) | 1997-12-29 |
| AU699476B2 (en) | 1998-12-03 |
| NO971685D0 (no) | 1997-04-11 |
| DE69526862T2 (de) | 2003-01-02 |
| JP3061862B2 (ja) | 2000-07-10 |
| FI971510A7 (fi) | 1997-04-11 |
| FI971510A0 (fi) | 1997-04-11 |
| CA2202623A1 (en) | 1996-04-25 |
| US5981559A (en) | 1999-11-09 |
| HUT77609A (hu) | 1998-06-29 |
| NO971685L (no) | 1997-06-13 |
| EP0786457B1 (de) | 2002-05-29 |
| WO1996011916A1 (en) | 1996-04-25 |
| AU3673095A (en) | 1996-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE218132T1 (de) | Azol-derivate | |
| NO940737D0 (no) | Antidepressive midler | |
| EP1329160A4 (de) | 4-acylaminopyrazol-derivate | |
| CA2311742A1 (en) | 6-amino-9-benzyl-8-hydroxypurine derivatives | |
| ATE126216T1 (de) | Pyrazolderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellung. | |
| ES2156155T3 (es) | Derivado de pirazol. | |
| ATE239732T1 (de) | Indol-derivat, verfahren zu dessen herstellung und dessen medizinische anwendung | |
| AR002761A1 (es) | Un compuesto derivado del triazol, su uso, una composicion farmaceutica que lo contiene, un metodo de tratamiento o prevencion de una infeccion fungica enun paciente humano mediante dicho compuesto o composicion, y procedimiento y compuestos intermedios para prepararlo. | |
| NO304486B1 (no) | Oksazolidonderivater og anvendelser derav, og midler og medisinske preparater omfattende slike oksazolidonderivater | |
| ATE169623T1 (de) | Dihydrobenzofuranderivate, ihre herstellung und verwendung | |
| ES2055235T3 (es) | Composicion anti-inflamatoria y/o antialergica que comprende derivados de glutation. | |
| DE69128630D1 (de) | Benzopyran derivat, seine darstellung und pharmazeutische zusammensetzung, welche dieses enthält | |
| ATE169015T1 (de) | Aminobenzoesäure derivate | |
| DE69001004D1 (de) | Zusammensetzung gegen leberkrankheiten. | |
| NO178540C (no) | Bisfenyletanderivater, farmasöytisk preparat derav samt anvendelse | |
| NO894325L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive pyrrolidin-derivater. | |
| DE69327077D1 (de) | Carbamoylpyrrolidon-Derivate zur Behandlung von Depressionen und cerebrovasculären Störungen | |
| ATE319452T1 (de) | Arzneimittel gegen essstörungen | |
| DE69325083D1 (de) | Imidazol-Derivate und ihre Verwendung als agrochemische Mittel | |
| ATE177106T1 (de) | Ymidothiophosphat-derivat und insektizid, nematozid und akarizid enthalted dasselbe als aktiven bestandteil. | |
| ATE241985T1 (de) | Therapeutisches mittel zur behandlung von nierenerkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |